Cookie Policy

Last updated: 07 September 2026

1. What are cookies?

Cookies are small text files that a website may store on a user's device for various purposes, such as enabling the proper functioning of the website or remembering certain preferences.

2. Use of cookies on this website

This website does not use non-essential cookies, such as analytics, advertising, personalization, or tracking cookies.

Where applicable, only strictly necessary technical cookies may be used to ensure the proper operation and security of the website. These cookies do not require the user's consent under applicable laws and regulations.

3. Third-party cookies

This website does not install third-party cookies for analytics, advertising, or profiling purposes.

If, in the future, services requiring the use of such cookies are introduced, the user's prior consent will be obtained through the appropriate cookie consent management system.

4. Cookie management

As this website does not use non-essential cookies, there is no need to configure cookie consent preferences.

Detailed challenge descriptions, background information, thematic sub-challenges, scope and constraints will be made available through the official Hackathon website and supporting documentation.

5. Changes to this Cookie Policy

This Cookie Policy may be updated to reflect legal, regulatory, or technical changes. Users are encouraged to review this page periodically to stay informed of the current version.

8. Jury & awards

At the end of the Hackathon day on 3rd of December 2026, each team will present its solution to a Jury appointed by Novartis.

The Jury will evaluate the final projects using the predefined evaluation criteria. One winning team will be selected for each Hackathon Challenge, resulting in a total of two winning teams.

The winning teams will receive recognition from Novartis through visibility and showcase opportunities within Novartis and, where appropriate, across the broader healthcare and innovation ecosystem. The nature, format and timing of such recognition shall be determined by Novartis at its sole discretion.

The Jury's decision shall be final and binding.